Drug's Effect on Macular Edema in Type 2 Diabetics Studied

Calcium dobesilate does not reduce risk of clinically significant disease or affect rates of adverse events

FRIDAY, April 17 (HealthDay News) -- In patients with type 2 diabetes who have mild-to-moderate non-proliferative diabetic retinopathy, calcium dobesilate does not reduce the risk of development of clinically significant macular edema, according to a study published in the April 18 issue of The Lancet.

Christos Haritoglou, M.D., of Ludwig-Maximilians-University in Munich, Germany, and colleagues randomly assigned 635 patients to calcium dobesilate or placebo.

The researchers found that there were no significant differences between the calcium dobesilate and placebo groups in estimated cumulative five-year clinically significant macular edema probability (35 percent versus 28 percent) or in the rates of adverse events (24 percent versus 29 percent).

"Of note, we saw no effect of study drug in men and women with good glycemic control and blood pressure in the normal range, and in specific subgroups of patients, placebo was significantly better than calcium dobesilate," the authors write. "Our data suggest that women with risk factors for vascular disease might benefit from treatment with calcium dobesilate, although this interpretation remains speculative."

This study was supported by Sanofi, OM Pharma, and Synthelabo.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing